Clinical Trial: Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Easy Identification, Treatment Response Prediction, and Molecular Mechanism Exploration of Antipsychotic-related Metabolic Syndrome

Brief Summary: The investigators developed an easy identification model to identify metabolic syndrome in patients with schizophrenia or schizoaffective disorder who received treatment of clozapine, olanzapine, or risperidone. The accuracy of the investigators' models showed well. In the study, the investigators aim to (1) to examine whether the developed identification models can be generalized to patients taking other antipsychotics or patients with other diagnoses; (2) to develop an easy risk score and validate it; (3) to switch antipsychotics to amisulpride or aripiprazole for those with metabolic syndrome, and compare the changes of metabolic parameters including adiponectin, and analyze their association with genetic variants, demography, and clinical variables; (4) to establish models using artificial neural network and statistic method to predict metabolic response after a switch to amisulpride or aripiprazole; (5) to investigate the effect of antipsychotics on adiponectin gene expression and secretion during the differentiation process of 3T3L1 adipocytes.

Detailed Summary:
Sponsor: National Taiwan University Hospital

Current Primary Outcome: Metabolic profile [ Time Frame: half/one year ]

Original Primary Outcome: Metabolic profile [ Time Frame: one year ]

Current Secondary Outcome: Clinical efficacy [ Time Frame: half/one year ]

Original Secondary Outcome: Clinical efficacy [ Time Frame: one year ]

Information By: National Taiwan University Hospital

Dates:
Date Received: August 10, 2009
Date Started: November 2009
Date Completion:
Last Updated: January 2, 2013
Last Verified: November 2012